Nomura Raises CSPC PHARMA (01093.HK) Price Target to $12.04, Maintains Buy Rating
CSPC Pharma Revenue Forecast: Nomura predicts CSPC Pharma's 4Q25 revenue will increase by 20% YoY to RMB7.6 billion, surpassing market expectations of RMB7.4 billion.
Sales and Profit Margin Estimates: The broker anticipates a slight decline in finished drug sales to RMB5 billion, while collaboration revenue is expected to reach RMB1.1 billion, with a gross profit margin increase to 68.5%.
Revised Financial Projections: Nomura has raised its FY2025/2026 revenue forecasts by 1% and 7.2%, respectively, and increased earnings forecasts by 5.9% and 26.4% due to higher collaboration revenue and profit margins.
Investment Rating and Target Price: The broker maintains a "Buy" rating for CSPC Pharma and has raised its target price from $9.11 to $12.04.
Trade with 70% Backtested Accuracy
Analyst Views on 01093
About the author
Nomura Raises CSPC PHARMA (01093.HK) Price Target to $12.04, Maintains Buy Rating
CSPC Pharma Revenue Forecast: Nomura predicts CSPC Pharma's 4Q25 revenue will increase by 20% YoY to RMB7.6 billion, surpassing market expectations of RMB7.4 billion.
Sales and Profit Margin Estimates: The broker anticipates a slight decline in finished drug sales to RMB5 billion, while collaboration revenue is expected to reach RMB1.1 billion, with a gross profit margin increase to 68.5%.
Revised Financial Projections: Nomura has raised its FY2025/2026 revenue forecasts by 1% and 7.2%, respectively, and increased earnings forecasts by 5.9% and 26.4% due to higher collaboration revenue and profit margins.
Investment Rating and Target Price: The broker maintains a "Buy" rating for CSPC Pharma and has raised its target price from $9.11 to $12.04.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
<Daily Summary> HSI Ends at 27,032, Dropping 233 Points; HSTI Finishes at 5,408, Decreasing by 91 Points; MEITUAN Falls More Than 4%; WUXI APPTEC, SHK PPT, SINOPEC CORP, CHINA RES MIXC, HK & CHINA GAS Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 233 points (0.9%) to close at 27,032, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.
Active Heavyweights: Major stocks like Meituan, Tencent, and Xiaomi saw significant drops, with Meituan down 4.5% and Tencent down 2.3%, amidst high short selling activity.
Notable Movers: Bud APAC and Lenovo Group faced substantial losses, with Bud APAC down 5.2%, while Zijin Mining and PICC P&C were among the few gainers, with Zijin Mining up 3.4%.
High Performers: Unisound and Guofuhee experienced remarkable gains, with Unisound rising by 16.8%, indicating strong market interest in these stocks.
<Midday Update> HSI Ends Midday at 27,023, Dropping 242 Points; HSTI at 5,407, Down 92 Points; MEITUAN Falls More Than 4%; WUXI APPTEC, WUXI BIO, SHK PPT, SINOPEC CORP, and HK & CHINA GAS Reach New Peaks
Market Performance: The Hang Seng Index (HSI) fell by 242 points (0.9%) to 27,023, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 1.7% and 1.0%, respectively.
Active Heavyweights: Major stocks like Meituan, Tencent, Alibaba, and Xiaomi saw significant drops, with Meituan down 4.2% and Tencent down 2.6%, amidst high short selling activity.
Notable Movers: Wuxi AppTec and Wuxi Bio both hit new highs, increasing by 3.9% and 3.7%, respectively, while Bud APAC and Trip.com saw declines of 5% and 4.3%.
Short Selling Trends: High short selling ratios were observed across various stocks, with NetEase Music experiencing the largest drop of 11.9%, while Fit Hon Teng and COSCO Ship Energy saw substantial gains of over 10%.
HSI Rises by 155 Points Driven by Surge in AI and Pharmaceutical Stocks
Market Performance: The HSI rose by 155 points (0.6%) to close at 27,183, with a total market turnover of HKD234.04 billion. The HSCEI and HSTECH also saw gains, closing at 9,242 and 5,451 respectively.
Tech Stock Movements: Major tech stocks like TENCENT and MEITUAN-W experienced declines of 1.6% and 2.5%, while KUAISHOU-W, JD-SW, and BABA-W saw increases between 1.6% and 1.9%.
AI and Pharma Stocks Surge: AI stocks such as UNISOUND and INSILICO rose significantly, with KNOWLEDGE ATLAS jumping 14.8% after JPMorgan initiated coverage. Pharma stocks also performed well, with CSPC PHARMA and INNOVENT BIO gaining between 4.7% and 5.5%.
Chip Sector Performance: SMIC gained 1.7%, while HUA HONG SEMI dipped 1.2%. Other chip-related stocks like INNOSCIENCE and BIREN TECH saw notable increases, with INNOSCIENCE rising 6.9%.
<Daily Summary> HSI Ends at 27,183, Gaining 155 Points; HSTI Finishes at 5,451, Up 33 Points; CSPC PHARMA Surges Over 5%; ZTO EXPRESS-W, WH GROUP, BOC HONG KONG, WHARF REIC, and HANG LUNG PPT Reach New Peaks; Market Activity Increases
Market Performance: The Hang Seng Index (HSI) rose by 155 points (0.6%) to close at 27,183, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains, with market turnover reaching $234.04 billion.
Active Heavyweights: Notable movements included Meituan down 2.5%, Alibaba up 1.6%, Tencent down 1.6%, and Xiaomi up 1.1%, with significant short selling activity across these stocks.
Top Gainers: CSPC Pharma, Innovent Bio, and Pop Mart were among the top gainers, with CSPC Pharma increasing by 5.5% and Pop Mart by 4.9%, while New Oriental saw a decline of 4.4%.
High Performers in HSMI & HSSI: China Literature surged by 15.4%, Vobile Group by 14.4%, and GeekPlus by 11%, indicating strong performance in smaller stocks within the market.
Nomura Raises CSPC PHARMA (01093.HK) Price Target to $12.04, Maintains Buy Rating
CSPC Pharma Revenue Forecast: Nomura predicts CSPC Pharma's 4Q25 revenue will increase by 20% YoY to RMB7.6 billion, surpassing market expectations of RMB7.4 billion.
Sales and Profit Margin Estimates: The broker anticipates a slight decline in finished drug sales to RMB5 billion, while collaboration revenue is expected to reach RMB1.1 billion, with a gross profit margin increase to 68.5%.
Revised Financial Projections: Nomura has raised its FY2025/2026 revenue forecasts by 1% and 7.2%, respectively, and increased earnings forecasts by 5.9% and 26.4% due to higher collaboration revenue and profit margins.
Investment Rating and Target Price: The broker maintains a "Buy" rating for CSPC Pharma and has raised its target price from $9.11 to $12.04.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
<Daily Summary> HSI Ends at 27,032, Dropping 233 Points; HSTI Finishes at 5,408, Decreasing by 91 Points; MEITUAN Falls More Than 4%; WUXI APPTEC, SHK PPT, SINOPEC CORP, CHINA RES MIXC, HK & CHINA GAS Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 233 points (0.9%) to close at 27,032, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.
Active Heavyweights: Major stocks like Meituan, Tencent, and Xiaomi saw significant drops, with Meituan down 4.5% and Tencent down 2.3%, amidst high short selling activity.
Notable Movers: Bud APAC and Lenovo Group faced substantial losses, with Bud APAC down 5.2%, while Zijin Mining and PICC P&C were among the few gainers, with Zijin Mining up 3.4%.
High Performers: Unisound and Guofuhee experienced remarkable gains, with Unisound rising by 16.8%, indicating strong market interest in these stocks.
<Midday Update> HSI Ends Midday at 27,023, Dropping 242 Points; HSTI at 5,407, Down 92 Points; MEITUAN Falls More Than 4%; WUXI APPTEC, WUXI BIO, SHK PPT, SINOPEC CORP, and HK & CHINA GAS Reach New Peaks
Market Performance: The Hang Seng Index (HSI) fell by 242 points (0.9%) to 27,023, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 1.7% and 1.0%, respectively.
Active Heavyweights: Major stocks like Meituan, Tencent, Alibaba, and Xiaomi saw significant drops, with Meituan down 4.2% and Tencent down 2.6%, amidst high short selling activity.
Notable Movers: Wuxi AppTec and Wuxi Bio both hit new highs, increasing by 3.9% and 3.7%, respectively, while Bud APAC and Trip.com saw declines of 5% and 4.3%.
Short Selling Trends: High short selling ratios were observed across various stocks, with NetEase Music experiencing the largest drop of 11.9%, while Fit Hon Teng and COSCO Ship Energy saw substantial gains of over 10%.
HSI Rises by 155 Points Driven by Surge in AI and Pharmaceutical Stocks
Market Performance: The HSI rose by 155 points (0.6%) to close at 27,183, with a total market turnover of HKD234.04 billion. The HSCEI and HSTECH also saw gains, closing at 9,242 and 5,451 respectively.
Tech Stock Movements: Major tech stocks like TENCENT and MEITUAN-W experienced declines of 1.6% and 2.5%, while KUAISHOU-W, JD-SW, and BABA-W saw increases between 1.6% and 1.9%.
AI and Pharma Stocks Surge: AI stocks such as UNISOUND and INSILICO rose significantly, with KNOWLEDGE ATLAS jumping 14.8% after JPMorgan initiated coverage. Pharma stocks also performed well, with CSPC PHARMA and INNOVENT BIO gaining between 4.7% and 5.5%.
Chip Sector Performance: SMIC gained 1.7%, while HUA HONG SEMI dipped 1.2%. Other chip-related stocks like INNOSCIENCE and BIREN TECH saw notable increases, with INNOSCIENCE rising 6.9%.
<Daily Summary> HSI Ends at 27,183, Gaining 155 Points; HSTI Finishes at 5,451, Up 33 Points; CSPC PHARMA Surges Over 5%; ZTO EXPRESS-W, WH GROUP, BOC HONG KONG, WHARF REIC, and HANG LUNG PPT Reach New Peaks; Market Activity Increases
Market Performance: The Hang Seng Index (HSI) rose by 155 points (0.6%) to close at 27,183, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains, with market turnover reaching $234.04 billion.
Active Heavyweights: Notable movements included Meituan down 2.5%, Alibaba up 1.6%, Tencent down 1.6%, and Xiaomi up 1.1%, with significant short selling activity across these stocks.
Top Gainers: CSPC Pharma, Innovent Bio, and Pop Mart were among the top gainers, with CSPC Pharma increasing by 5.5% and Pop Mart by 4.9%, while New Oriental saw a decline of 4.4%.
High Performers in HSMI & HSSI: China Literature surged by 15.4%, Vobile Group by 14.4%, and GeekPlus by 11%, indicating strong performance in smaller stocks within the market.
